MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice

References

• ShererYGorsteinAFritzlerMJShoenfeldYAutoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patientsSemin Arthritis Rheum200434250153715505768
   PubMed Web of Science ®Google Scholar
• RahmanAIsenbergDASystemic lupus erythematosusN Engl J Med2008358992993918305268
   PubMed Web of Science ®Google Scholar
• Yildirim-TorunerCDiamondBCurrent and novel therapeutics in the treatment of systemic lupus erythematosusJ Allergy Clin Immunol2011127230331421281862
   PubMed Web of Science ®Google Scholar
• BaggaSBrachtJHunterSRegulation by let-7 and lin-4 miRNAs results in target mRNA degradationCell2005122455356316122423
   PubMed Web of Science ®Google Scholar
• DaiRAhmedSAMicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseasesTransl Res2011157416317921420027
   PubMed Web of Science ®Google Scholar
• CeribelliAYaoBDominguez-GutierrezPRNahidMASatohMChanEKMicroRNAs in systemic rheumatic diseasesArthritis Res Ther201113422921787439
   PubMed Web of Science ®Google Scholar
• GarchowBGEncinasOBLeungYTSilencing of microR6-21 in vivo ameliorates autoimmune splenomegaly in lupus miceEMBO Mol Med201131060561521882343
   PubMed Web of Science ®Google Scholar
• LiLChenXPLiYJMicroRNA-146a and human diseaseScand J Immunol201071422723120384865
   PubMed Web of Science ®Google Scholar
• TangYLuoXCuiHMicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteinsArthritis Rheum20096041065107519333922
   PubMed Web of Science ®Google Scholar
• BoldinMPTaganovKDRaoDSmiR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in miceJ Exp Med201120861189120121555486
   PubMed Web of Science ®Google Scholar
• DavidsonBLJrMcCrayPBCurrent prospects for RNA interference-based therapiesNat Rev Genet201112532934021499294
   PubMed Web of Science ®Google Scholar
• WangJLuZWientjesMGAuJLDelivery of siRNA therapeutics: barriers and carriersAAPS J201012449250320544328
   PubMed Web of Science ®Google Scholar
• WangJEfficient gene knockdowns in mouse embryonic stem cells using microRNA-based shRNAsMethods Mol Biol201065024125620686956
   PubMedGoogle Scholar
• CarricoZMRomaniniDWMehlRAFrancisMOxidative coupling of peptides to a virus capsid containing unnatural amino acidsChem Commun (Camb)200814101205120718309418
   PubMed Web of Science ®Google Scholar
• KovacsEWHookerJMRomaniniDWHolderPGBerryKEFrancisMBDual-surface-modified bacteriophage MS2 as an ideal scaffold for a viral capsid-based drug delivery systemBioconjugate Chem200718411401147
   PubMed Web of Science ®Google Scholar
• WuMSherwinTBrownWLStockleyPGDelivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsidsNanomedicine200511677617292060
   PubMed Web of Science ®Google Scholar
• PanYZhangYJiaTZhangKLiJWangLDevelopment of a microRNA delivery system based on bacteriophage MS2 virus-like particlesFEBS J201227971198120822309233
   PubMed Web of Science ®Google Scholar
• LivakKJSchmittgenTDAnalysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) MethodMethods200125440240811846609
   PubMed Web of Science ®Google Scholar
• WeiBWeiYZhangKDevelopment of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptideBiomed Pharmacother2009643313318
   Web of Science ®Google Scholar
• IzuiSIbnou-ZekriNFossati-JimackLIwamotoMLessons from BXSB and related mouse modelsInt Rev Immunol2000194–544747211016427
   PubMedGoogle Scholar
• XuJZutterMMSantoroSAClarkRAA three-dimensional collagen lattice activates NF-kappaB in human fibroblasts: role in integrin alpha2 gene expression and tissue remodelingJ Cell Biol199814037097199456329
   PubMed Web of Science ®Google Scholar
• NahidMAPauleyKMSatohMChanEKMiR-146a is critical for endotoxin-induced tolerance: IMPLICATION IN INNATE IMMUNITYJ Biol Chem200928450345903459919840932
   PubMed Web of Science ®Google Scholar
• DaiYSuiWLanHYanQHuangHHuangYComprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patientsRheumatol Int200929774975418998140
   PubMed Web of Science ®Google Scholar
• TeJLDozmorovIMGuthridgeJMIdentification of unique microRNA signature associated with lupus nephritisPLoS One20105510344
   PubMed Web of Science ®Google Scholar
• DaiRZhangYKhanDIdentification of a common lupus disease-associated microRNA expression pattern in three different murine models of lupusPLoS One201051214302
   Web of Science ®Google Scholar
• SethupathyPCollinsFSMicroRNA target site polymorphisms and human diseaseTrends Genet2008241048949718778868
   PubMed Web of Science ®Google Scholar
• HuppiKVolfovskyNMackiewiczMMicroRNAs and genomic instabilitySemin Cancer Biol2007171657317113784
   PubMed Web of Science ®Google Scholar
• SelbachMSchwanhausserBThierfelderNFangZKhaninRRajewskyNWidespread changes in protein synthesis induced by microRNAsNature20084557209586318668040
   PubMed Web of Science ®Google Scholar
• PerryDSangAYinYZhengYYMorelLMurine models of systemic lupus erythematosusJ Biomed Biotechnol2011201127169421403825
   PubMedGoogle Scholar
• KonoDHHaraldssonMKLawsonBREndosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupusProc Natl Acad Sci U S A200910629120611206619574451
   PubMed Web of Science ®Google Scholar
• LeadbetterEARifkinIRHohlbaumAMBeaudetteBCShlomchikMJMarshak-RothsteinAChromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptorsNature2002416688160360711948342
   PubMed Web of Science ®Google Scholar
• Marshak-RothsteinAToll-like receptors in systemic autoimmune diseaseNat Rev Immunol200661182383517063184
   PubMed Web of Science ®Google Scholar
• NickersonKMChristensenSRShupeJTLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupusJ Immunol201018441840184820089701
   PubMed Web of Science ®Google Scholar
• BhaumikDScottGKSchokrpurSPatilCKCampisiJBenzCCExpression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cellsOncogene200827425643564718504431
   PubMed Web of Science ®Google Scholar
• PauleyKMSatohMChanALBubbMRReevesWHChanEKUpregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patientsArthritis Res Ther200810410118226182
   PubMed Web of Science ®Google Scholar
• BanchereauJPascualVType I interferon in systemic lupus erythematosus and other autoimmune diseasesImmunity200625338339216979570
   PubMed Web of Science ®Google Scholar
• GrondalGGunnarssonIRonnelidJRogbergSKlareskogLLundbergICytokine production, serum levels and disease activity in systemic lupus erythematosusClin Exp Rheumatol200018556557011072595
   PubMed Web of Science ®Google Scholar
• TackeyELipskyPEIlleiGGRationale for interleukin-6 blockade in systemic lupus erythematosusLupus200413533934315230289
   PubMed Web of Science ®Google Scholar
• YokoyamaHKreftBKelleyVRBiphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanismsKidney Int19954711221307731137
   PubMed Web of Science ®Google Scholar
• BrennanDCYuiMAWuthrichRPKelleyVETumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injuryJ Immunol198914311347034752584702
   PubMed Web of Science ®Google Scholar
• RaoDDSenzerNClearyMANemunaitisJComparative assessment of siRNA and shRNA off target effects: what is slowing clinical developmentCancer Gene Ther2009161180780919713999
   PubMed Web of Science ®Google Scholar
• SinghSNarangASMahatoRISubcellular fate and off-target effects of siRNA, shRNA, and miRNAPharm Res201128122996301522033880
   PubMed Web of Science ®Google Scholar